Clinical Trials Browser

Adebrelimab (SHR-1316) × 1 year × Clear all

NCT07035392 2025-06-25

Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

Phase 2 Not yet recruiting

Adebrelimab (SHR-1316)